Medicare AdvantageCoverageMedium impact
MA08.153c, Risankizumab-rzaa (Skyrizi®) for intravenous use
Independence Blue Cross·Dermatology, Rheumatology, Gastroenterology·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.153c for Risankizumab-rzaa (Skyrizi®) intravenous use has been reissued with an effective date of November 26, 2025. This policy update affects coverage and billing requirements for this specialty biologic medication used primarily for inflammatory conditions.
Action Required
By November 26, 2025: Billing team must review updated Medicare Advantage policy MA08.153c for Risankizumab-rzaa (Skyrizi®) intravenous use to understand any changes in coverage criteria, prior authorization requirements, or billing procedures. Monitor for detailed policy content as only summary information is currently available.